Because the drug doesn’t target the brain, it has less potential for addiction. Learn why this could help the opioid crisis.
The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...
On Wednesday, the U.S. Food and Drug Administration approved a new pain management drug which could change the way healthcare ...
The U.S. Food and Drug Administration said it approved Boston-based Vertex Pharmaceuticals' Journavx for short-term pain that ...
The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or ...
The FDA has approved a new type of pain pill designed to eliminate the risks of addiction and overdose associated with opioid ...
The new drug will carry a list price of $15.50 per pill, making it many times more expensive than comparable opioids.
One participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous, which ...